Anti ICAM-1 (CD 54) monoclonal antibody reduces inflammatory changes in experimental bacterial meningitis

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Bacterial meningitis causes brain edema and increased intracranial pressure.
• The role of intracellular adhesion molecule 1 (ICAM-1) in early meningitis pathogenesis is not fully understood.

Purpose of the Study:

• To investigate the therapeutic potential of ICAM-1 monoclonal antibodies (mAbs) in early bacterial meningitis.
• To assess the effects of ICAM-1 blockade on brain edema, intracranial pressure, cerebral blood flow, and white blood cell infiltration.

Main Methods:

• A rat model of bacterial meningitis was established using pneumococcal cell walls (PCW).
• Intravenous administration of ICAM-1 mAb (TM-8) was performed.
• Brain water content, intracranial pressure (ICP), regional cerebral blood flow (rCBF), and cerebrospinal fluid (CSF) white blood cell (WBC) counts were measured.

Main Results:

• ICAM-1 mAb treatment significantly inhibited increases in ICP and brain water content (P <0.05).
• Treatment with ICAM-1 mAb markedly attenuated increases in rCBF and WBC recruitment into the CSF (P <0.05).

Conclusions:

• The ICAM-1 pathway plays a critical role in the early stages of bacterial meningitis.
• Targeting ICAM-1 with monoclonal antibodies shows promise for treating early bacterial meningitis by reducing key pathological markers.